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FKBP38Non-capacitative calcium entry (NCCE) contributes to cell activation in response to the occupation of G protein-
coupledmembrane receptors. Thrombin administration to platelets evokes the synthesis of diacylglycerol down-
stream of PAR receptor activation. Diacylglycerol evokes NCCE through activating TRPC3 and TRPC6 in human
platelets. Although it is known that immunophilins interact with TRPCs, the role of immunophilins in the
regulation of NCCE remains unknown. Platelet incubation with FK506, an immunophilin antagonist, reduced
OAG-evoked NCCE in a concentration-dependent manner, an effect that was independent on the inactivation
of calcineurin (CaN). FK506 was unable to reduce NCCE evoked by OAG in platelets from TRPC6−/− mice. In
HEK-293 cells overexpressing TRPC6, currents through TRPC6 were altered in the presence of FK506. We have
found interaction between FKBP38 and other FKBPs, like FKBP25, FKBP12, and FKBP52 that were not affected
by FK506, as well as with calmodulin (CaM). FK506 modiﬁed the pattern of association between FKBP25 and
TRPCs as well as impaired OAG-evoked TRPC3 and TRPC6 coupling in both human and mouse platelets. By
performing biotinylation experiments we have elucidated that FKBP25 and FKBP38 might be found at different
cellular location, the plasma membrane and the already described intracellular locations. Finally, FKBP25 and
FKBP38 silencing signiﬁcantly inhibits OAG-evoked NCCE in MEG-01 and HEK293 cells, while overexpression
of FKBP38 does not modify NCCE in HEK293 cells. All together, these ﬁndings provide strong evidence for a
role of immunophilins, including FKBP25 and FKBP38, in NCCE mediated by TRPC6.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
In human platelets, Ca2+ entry from the extracellular medium is a
key signaling event for both secretion and aggregation upon occupation
of the plasmamembrane receptors. Twomajor receptor-operated Ca2+
inﬂuxmechanisms have beendescribed in these cells: store-operated or
capacitative Ca2+ entry (SOCE) and non-capacitative Ca2+ entry (NCCE)
[1–4]. In human platelets, and other cell types, bothmechanismswould
occur simultaneously upon the activation of G protein-coupled recep-ilins; FKBD, FK506-binding do-
doplasmic Ca2+-ATPase; IP3Rs,
isphosphate; TRPC, transient re-
olimus; CaN, calcineurin; CaM,
e-calcium concentration; Thr,
SOCE, store-operated calcium
romal interaction molecule 1;
G, 1-oleoyl-2-acetyl-glycerol;
rum albumin; PRP, plasma rich
e dextrose buffer; TBST, tris-
nt; WT, wild type; CAP, control
salt; WCL, whole cell lysatetors and, subsequently, phospholipase C, which, in turn, generates diac-
ylglycerol and inositol 1,4,5-trisphosphate (IP3) [5]. IP3 mobilizes Ca2+
from the internal stores, leading to the activation of the stromal interac-
tion molecule 1 (STIM1) [6–8], which regulates the activation of the
store-operated Ca2+ (SOC) channels in the plasmamembrane. Simulta-
neously, diacylglycerol either directly or indirectly gates non-
capacitative Ca2+ channels [5,9].
It has been claimed that certain TRPC and Orai subunits form the
channels involved inNCCE [4,10–12]. In humanplatelets, it has been de-
scribed the generation of the TRPC1/4/5 and TRPC3/6 heteromultimeric
complexes in response to physiological agonists [13]. In this cell type, it
has been generally accepted that NCCE mechanism is conducted by
heteromultimeric channels resulting from the association between
TRPC3 and TRPC6 [14–16].
The immunophilin family comprises immunophilins (FKBPs),
cyclophilins (Cyps), and junglone. They are chaperone proteins with
peptidyl-prolyl isomerase activity [17]. Regarding FKBP subfamily struc-
ture, FKBP12 shows the most basic structure among the members of the
FKBP subfamily, containing just one FK506-binding domain (FKBD).
Other FKBPs, like FKBP52 and FKBP64, have two or three FKBD domains
[17]. The afﬁnity of the FKBD region for FK506 is different among the
members of the family and some FKBPs have afﬁnity for other macrolide
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more afﬁnity for rapamycin than for FK506 [18,19]. In the presence of
FK506, FKBPs interfere with calcineurin activity; meanwhile, in cells in-
cubated with rapamycin, FKBPs interact with and inhibit mTOR activity,
which participates in the cell cycle by downregulating the PI3K/
AKTPKB/mTOR complex. Moreover, the FKBD region might be mutated
such as in the case of FKBP38 [20], whichwas not considered to have nei-
ther peptidyl-prolil isomerase activity nor FK506 afﬁnity. In fact, FKBP38
has a very anomalous structure as compared to other immunophilin
members, since it presents three TPR domains and a leucine-zipper re-
peat that facilitate its interactionwith other proteins [20]. The FKBP38 ac-
tivity and its association with FK506 were later demonstrated, although
it was subordinated to previous complexingwith CaM [21,22]. The intra-
cellular location of the FKBPmembers might differ. For instance, FKBP25
and FKBP133 are mostly located in the nucleus; meanwhile FKBP12,
FKBP25, FKBP38, FKBP51, and FKBP52, are located in the ER and mito-
chondrial membranes, or in the proximity of the ribosomes, like
FKBP38 and FKBP25. FKBP38 has a particular C-terminal domain and
three TPR domains that facilitate the associations to cellular membranes,
such as the mitochondrial membrane, and the interaction with other
proteins, respectively [17]. FKBP51might change their intracellular local-
ization, migrating from the mitochondria to the nucleus [17,23].
FKBPs regulate intracellular Ca2+homeostasis by interactingwith dif-
ferent Ca2+ channels, like ryanodine or IP3 receptors [24–28]. FKBPs also
interactwithplasmamembraneCa2+ channels. For instance, FKBP12 and
FKBP52 interact with TRPCs [29–32] and in human platelets, Orai1 and
TRPC1 interact with FKBP12 and FKBP52 in response to thrombin (Thr)
or the SERCA inhibitor, thapsigargin [30]. Studies in cells from the rat ce-
rebral cortex and HEK cells have revealed that FKB12 interacts with
TRPC3, TRPC6, and TRPC7; while FKBP52 interacts with TRPC1, TRPC4,
and TRPC5 [29]. Furthermore, TRPC6 overexpressed in HEK293 interacts
with the native FKBP13 [29]. Hence, in the present study we have inves-
tigated the role of FKBPs in the activation of NCCE in non-excitable cells.
2. Experimental
2.1. Materials
Fura-2 acetoxymethyl ester (fura-2/AM) and ﬂuo-4 acetoxymethyl
ester (ﬂuo-4/AM) were from Molecular Probes (Leiden, The
Netherlands). Apyrase (grade VII), adenosine 5′-diphosphate sodium
salt (ADP), aspirin, dithiothreitol (DTT), sodium dodecyl sulfate (SDS),
ionic detergent tween 20 (Tween-20), Na3VO4, cypermethrin, bovine
serum albumin (BSA), geneticin G418 disulfate salt solution, and
anti-actin antibody were from Sigma® (Madrid, Spain). FK506 was from
Selleck Chemical® (Huston, Texas, U.S.A.). OAG was from Calbiochem®
(Merck© Millipore, Darmstadt, Germany, UK). Protein A-agarose was
from Upstate Biotechnology (Lake Placid, NY, U.S.A.). Amaxa Kit-C for
MEG-01 transfection and culture media were from Lonza® (Cultek,
Madrid, Spain). Goat IgG antibody, anti-FKBP38 antibody, siRNA control,
and siRNAs against FKBP25 and FKBP38 were purchased from Santa
Cruz biotechnology Inc. (Texas, U.S.A.). FKBP38 overexpression was
achieved using the vector of expression pEGFP-C1 containing the fused
protein eGFP-FKBP38 that was kindly provided by Dr. Gunter Fischer
(Max Planck Research Unit for Enzymology of Protein Folding, Halle/
Saale, Germany). Transfecting Lipid Reagent was from Bio-Rad (Madrid,
Spain). The anti-PMCA, anti-calmodulin, anti-TRPC6, anti-TRPC3, and
anti-TRPC1 antibodies were from Alomone (Jerusalem, Israel). Horserad-
ish peroxide-conjugated anti-rabbit or anti-mouse IgG antibodies,
hyperﬁlm ECL and molecular weight markers were from GE Healthcare
Ltd (Chalfont St. Giles, UK). All other reagents were of analytical grade.
2.2. Animals
TRPC6-deﬁcient (TRPC6 KO) and wild type (WT) mice were pur-
chased from Deltagen, Inc. (San Mateo, CA) through the EuropeanMouse Mutant Archive (EMMA) network (B6;129P2-Trpc6tm1Dgen/
H; http://www.emmanet.org/deltagen/DELTAGEN_T881/). Brieﬂy, mu-
rine TRPC6 allele expression was disrupted by substitution of 13 nucle-
otides located into the exon four (E4) with a selection cassette
containing an internal ribosome entry site,β-galactosidase and the neo-
mycin resistant gene. Chimeric mice were backcrossed with C56BL/6
mice to obtain the ﬁrst generation of heterozygous mice, which were
subsequently intercrossed to obtain homozygous mice for the Trpc6-
null allele. TRPC6 silencing using this crossing has been previously re-
ported by our research group [33,34]. All experiments were conducted
in mice between 8 and 12 weeks of age in accordance with the regula-
tions of the Local Ethical Committee.
2.3. Human and mouse platelet preparations
Human platelets were prepared as described previously [30,35].
Brieﬂy, blood was obtained from healthy drug-free volunteers and
mixed with one-sixth volume of acid/citrate dextrose anticoagulant
containing (inmM): 85 sodium citrate, 78 citric acid, and 111 D-glucose.
Platelet-rich plasma (PRP) was then prepared by centrifugation for
5 min at 700 ×g and then aspirin (100 μM) and apyrase (40 μg/mL)
were added. Platelets were then centrifuged at 350 ×g for 20 min, and
resuspended in HEPES-buffered saline (HBS) containing (in mM): 145
NaCl, 10HEPES, 10 D-glucose, 5 KCl, 1MgSO4, pH 7.45, and supplement-
ed with 0.1% w/v bovine serum albumin and 40 μg/mL apyrase.
Mice were bled through the retro orbital plexus upon being anesthe-
tizedwith isoﬂurane [33,34] and bloodwas collected into a test tube con-
taining 300 μL of ACD. Mouse blood was centrifuged in a Galaxy 7D
centrifuge (VWR International, PA, U.S.A.) at 300 ×g for 5min. The super-
natant was centrifuged again at 100 ×g for 5 min to obtain the PRP. PRP
was centrifuged at 600 ×g for 5 min in the presence of aspirin
(0.1 μg/mL) and the pellet was resuspended in Ca2+-free Tyrode's buffer
(NaCl 137 mM, KCl 2.7 mM, NaHCO3 12 mM, NaH2PO4 0.43 mM, glucose
0.1%, HEPES 5 mM, BSA 0.35%, CaCl2 1 mM, MgCl2 1 mM, pH 7.13) con-
taining apyrase (40 μg/mL).
2.4. Culture cell lines and protein silencing
HEK293 cells, stably expressing TRPC6, were grown using DMEN
supplemented with antibiotics and 10% FBS at 37 °C with 5% CO2. HEK
293 cells were detached from the culture dish using trypsin solution
(0.25% trypsin + 0.1% EDTA) and stored in the culture medium at
room temperature for patch-clamp experiments within 5 h [36,37]. Ad-
ditionally, for Ca2+ experiments, cells were passed to a 96 hole plate
24 h before the beginning of the experiments.
The human megakaryoblastic cell line MEG-01 was obtained from
ATCC (Manassas, VA, U.S.A.) and cultured at 37 °C and 5% CO2 in RPMI
media, supplemented with 10% FCS, 2 mM L-glutamine and antibiotics.
MEG-01 cells were transiently transfected, in parallel experiments,
with siRNA control, siRNA FKBP25 and siRNA FKBP38, using the kit-C
and following manufacturer's instructions [31,38]. Two micrograms of
siRNA control, siRNA FKBP25, and siRNA FKBP38 were added to the cu-
vette. Upon transfection, cells were transferred to fresh medium and
kept for 72 h. Protein silencing was veriﬁed by Western blotting using
speciﬁc antibodies as described below. Additionally, HEK293 cells at
60–90% conﬂuence were transfected with 10 μg siRNA FKBP25 and
siRNA FKBP38 using Transfecting Lipid Reagent. Upon 5 h of incubation
at 37 °C with the mix, cells were supplemented with fresh medium and
they were analyzed 72 h after transfection.
Finally, HEK293 cells were transfected with a FKBP38 overexpres-
sion plasmid using the vector of expression pEGFP-C1 containing the
fused protein eGFP-FKBP38 (2 μg/mL) and the Transfecting Lipid Re-
agent following the manufacturer's instructions. 24 h after transfection,
cells positively transfected were identiﬁed using an epiﬂuorescence mi-
croscope equipped with a 60× objective.
Fig. 1. FK506 reduces NCCE independently of its inhibitory effect in CaN activity. (A) Fura-2-loaded human platelets resuspended in Ca2+ free HBS medium (75 μM EGTA was added as
indicated with the arrowhead) and they were subsequently stimulated with OAG (100 μM). (B) Fura-2-loaded human platelets were suspended in HBS medium containing 300 μM
Ca2+ and preincubated for 5 min with increasing concentration of FK506 (0.5–50 μM), after which OAG (100 μM) was added to initiate NCCE. (C) NCCE was stimulated by adding OAG
(100 μM) to platelets suspended in HBS containing 300 μM Ca2+ and previously incubated for 30 min in the absence or presence of the CaN inhibitor cypermethrin (100 nM, cyper)
alone or in combination with FK506 (50 μM) that was added to the cuvette 5 min before starting the Ca2+ records. Graphs represent the mean ± standard deviation of six independent
experiments using different blood donors. Histograms represent OAG-evoked Ca2+ entry expressed as percentage of control (cells not treatedwith FK506). Data are presented asmean±
S.E.M. *, **, ***: represent P b 0.05, b0.01, and b0.001, as compared to control, respectively.
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PRP obtained from both human and mouse blood was incubated at
37 °Cwith 2 μMof fura-2/AM for 40min in order to evaluate the chang-
es in the [Ca2+]c evoked during platelets activation. Fluorescence was
recorded using a spectroﬂuorophotometer (Cary Eclipse, Varian,
Madrid) in 2mL aliquots ofmagnetically stirred human platelet suspen-
sions (108 cells/mL in HBS) at 37 °C. Mouse platelets were suspended in
600 μL of tyrode's buffer containing 50 μM of CaCl2, and the [Ca2+]c was
monitored using a RF-5301PC spectroﬂuorophotometer (Shimadzu®,
Japan). Samples were alternatively excited at the wavelengths of 340
and 380 nm and emission was recorded at 510 nm. Changes in [Ca2+]c
were determined using the fura-2 340/380 ﬂuorescence ratio and cali-
brated according to the method of Grynkiewicz [39]. Alternatively,
MEG-01 cells were incubated for 30 min with 2 μM of fura-2/AM at
room temperature, centrifuged for 2 min at 100 ×g, and then resus-
pended in fresh HBS medium supplemented with 50 μM of CaCl2.
MEG-01 and HEK293 cells were transferred to a perfusion chamber
that was placed under an inverted microscope. Emission of fura-2 ﬂuo-
rescence as result of changes in the [Ca2+]c inMEG-01 andHEK293 cells
were monitored using a single-cell conﬁguration equipment and was
processed using Aquacosmos software (Hamamatsu ®, Japan). Data
are expressed as the change in ﬂuorescence after the addition of differ-
ent stimulus (Fn) divided by theﬂuorescence emitted by the cells under
resting conditions (Fo). Finally, HEK293 cells overexpressing TRPC6
were loaded with ﬂuo-4 by incubating the cells for 60 min at 37 °C.
[Ca2+]c in HEK293 cells were monitored using a Flexstation 3 system
(Molecular Devices®, U.S.A.), in which cells were stimulated by
100 μM of OAG, 300 μM of CaCl2, using a robotic arm, and following
the setting established by the main handling control unit.Fig. 2.NCCE entry is not affected by FK506 inmurine TRPC6−/− platelets. Fura-2-loadedplatelet
Ca2+ rich medium, respectively. Platelet suspensions were then incubated for 5 min with FK50
mean ± standard deviation of six independent experiments using 9 different mice of 8 to 10 w
controls. ***: P b 0.001.2.6. Patch-clamp experiments
Whole-cell patch-clamp recordings were performed as previously
described elsewhere [36,37]. Patch pipette solution contained (in
mM): 40 EGTA, 10 HEPES, 48 L-glutamic acid, 8 NaCl, 2 MgCl2, 10 Na2
ATP, 10 Hepes, 17 CaCl2 (osmolarity was adjusted to ∼300 mOsm with
mannitol and pH was titrated to 7.2 using CsOH). The extracellular
(bath) solution contained (in mM): 140 NaCl, 5 KCl, 1.2 MgCl2, 1
BaCl2, 10 HEPES, 10 glucose (osmolarity ∼290 mOsm and pH 7). A
salt-agar bridge was used to connect the Ag–AgCl ground wire to the
bath. Signals were ampliﬁed with an Axopatch 200B patch-clamp am-
pliﬁer and controlled with Signal software 3.05 (CED). A 200 ms ramp
protocol from −100 mV to +100 mV was applied at a frequency of
0.1 Hz from a holding potential of−60 mV. Current signals were ana-
logue ﬁltered (Bessel) at 1 kHz and digitally sampled at 3 kHz. TRPC6
current was measured at -80 and +80 mV, and the differences in the
current between control and FK506-treated cells were estimated and
represented as % respect to control.2.7. Platelet aggregation
Platelets were suspended in 400 μL of HBS and incubated for 1 h
at 37 °C with 1 μg/mL of rabbit anti-TRPC6 antibody, 1 μg/mL of rab-
bit IgG or 1 μg/mL anti-TRPC6 antibody neutralized by
preincubation for 1 h with 1 μg/mL CAP. Platelet aggregation stimu-
lated by 10 μM ADP was monitored in the presence of 1 mM CaCl2
using a Chronolog aggregometer (Havertown, Pa, U.S.A.). Platelets
were kept during the experiments at 37 °C under stirring conditions
(1200 rpm) [65].swere drawn fromWT (A) and TRPC6−/−mice (B), andwere suspended in tyrode's buffer-
6 (50 μM), upon which NCCE was stimulated with 100 μM of OAG. Graphs represents the
eeks old, while histograms show the average of the percentage and S.E.M. respect to the
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Aliquots of 500 μL of platelets (1 × 108 cells/mL) were suspended in
HBS andwere centrifuged and resuspended in PBS/EDTA (500 μM), and
the cells were then centrifuged (600 ×g for 5 min). Pellet was then
suspended in biotynilation buffer containing: 50 mM NaHCO3 + 0.9%
NaCl. Finally, 150 μL of biotin-containing buffer was added and then
were incubated for 1 h at ice-cold temperature. The biotinylation reac-
tion was terminated by addition of 1% NH4Cl and then we supplement-
ed the buffer with 100 μL of PBS/EDTA (500 μM). Following
biotinylation, cells were washed four times in PBS/EDTA, and resus-
pended in IP buffer and subsequently lysed with IGEPAL (2% solution
was mixed). Samples were incubated with 25 μL streptavidin beads
overnight at 4 °C and resuspended in Laemmli's buffer for subsequent
analysis by Western blotting.
2.9. Immunoprecipitation and Western blotting
Aliquots (500 μL) of humanplatelet suspensions (109 cells/mL)were
stimulated with OAG in the absence or presence of FK506, and then,
cells were lysed by mixing with an equal volume of lysis buffer, RIPA
(2×) (pH 7.2) containing; 316 mM NaCl, 20 mM Tris, 2 mM EGTA,
0.2% SDS, 2% sodium deoxycholate, 2% triton X-100, 2 mM Na3VO4,
2 mM phenylmethylsulfonyl ﬂuoride, 100 μg/mL leupeptin andFig. 3. FK506 almost completely abolishes the TRPC6 current and Ca2+ permeability in HEK293
in D-MEN over coverslips. (A) Patch-clamp experiments were performed to monitor TRPC6-de
inhibition of the hTRPC6 currents activated byOAG (100 μM) is represented on the left hand side
densities of OAG-activated hTRPC6 are represented in the right hand side. Gd3+ was added to t
TRPC6 permeability. (B) HEK293 cells constitutively expressing TRPC6, were culture in DMEN o
added to the 96-holeplate. Fluo-4 loaded cellswere incubated in thepresenceor absenceof FK5
changes were analyzed using a Flexstation system®. Patch-clamp results are representative of
and expressed as mean ± standard deviation of changes in the arbitrary unit of ﬂuo-4 ﬂuoresc
stimulus. ***: P b 0.001, as compared to control.10 mM benzamidine. MEG-01 and HEK293 cells were lysed in buffer
NP-40 (2×) containing: 40 Tris-HCl, 277NaCl, 20% Glycerol, 2% Nonidet,
4 EDTA. Aliquots of platelets, MEG-01 and HEK293 cell lysates (1 mL)
were immunoprecipitated by incubating cells with 1 μg/mL of anti-
TRPC6, anti-FKBP25, anti-FKBP38 antibodies, rabbit IgG, and 25 μL of
protein A-agarose overnight at 4 °C on a rocking platform. The immuno-
precipitates were solved by 10% SDS-PAGE and separated proteinswere
electrophoretically transferred onto nitrocellulose membranes for sub-
sequent probing. Blots were incubated overnight in tris-buffered saline
with 0.1% Tween 20 containing 10% (w/v) BSA (TBST) to block residual
protein binding sites. Immunodetection was achieved using the anti-
TRPC6 antibody diluted 1:1000 in TBST, anti-TRPC3 antibody diluted
1:1000 in TBST, anti-TRPC1 antibody diluted 1:200 in TBST, anti-CaMdi-
luted 1:500 in TBST, anti-FKBP12 diluted 1:500 in TBST, anti-FKBP25 di-
luted 1:500 in TBST, anti-FKBP38 diluted 1:500 in TBST, anti-FKBP52
diluted 1:500 in TBST, and incubated for 2 h, or using an anti-actin anti-
body incubated for 1 h at 4 °C and diluted 1:1000 in TBST. The primary
antibody was removed and blots were washed six times for 5 min each
with TBST. To detect the primary antibody, blots were incubated with
the appropriate horseradish peroxidase-conjugated secondary antibody
diluted 1:10,000 in TBST, depending on the primary antibody used, and
then exposed to enhanced chemiluminescence reagents for 5 min.
Non-speciﬁc bands due to the secondary antibodies were assessed
by reprobing the membranes in the absence of primary antibodies.cells overexpressing TRPC6. HEK293 constitutively expressing TRPC6 cell linewere culture
pendent current in presence or absence of FK506 (50 μM). Time course of FK506-evoked
; current amplitudesweremeasured at -80mV and+80mV. Inward and outward current
he chamber at the end of each cuvette to corroborate that the current monitored relay on
ver coverslips and they were detached 24 h before the beginning of the experiments and
06 (50 μM) for 5min, and theywhere automatically stimulatedwithOAG (100 μM). [Ca2+]c
nine independent experiments, while Flexstation experiments were reproduced six times
ence (Fn/F0) of 4 independent experiments, F0: ﬂuo-4 ﬂuorescence unit before adding the
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C-digit device (Licor®). The density of bands on the ﬁlm was mea-
sured using the Image J free software from NIH. Biotinylated samples
were additionally developed using anti-PMCA antibody (1 h;
1:1000) in order to demonstrate that similar amount of proteins
have been biotinylated independently of the stimulation procedure
apply to platelets. Stripping of the membranes and reprobing using
antibody against the immunoprecipitated proteins or with anti-
actin antibody was done to corroborate that a similar amount of pro-
tein was loaded in each lane.
2.10. Statistical analysis
Analysis of statistical signiﬁcance was performedwith Student's un-
paired t test. For multiple comparisons, a one-way analysis of variance
combined with the Dunnett tests was used.
3. Results
3.1. Immunophilins are involved in NCCE in human platelets
Association to and regulation of SOCE channels by FKBPs have been
previously demonstrated [29,31,32], but their role in NCCE remains
poorly investigated. As shown in Fig. 1, OAG (100 μM) was unable to
evoke changes in the basal [Ca2+]c in human platelets suspended in a
Ca2+-free medium; meanwhile an increase in [Ca2+]c was observed
when 300 μM of CaCl2 was added to the extracellular medium
(Fig. 1A), thus indicating that OAG activates NCCE, as previously report-
ed in platelets and other cell types [4,40–43]. Preincubation of human
platelets for 5 min at 37 °C with increasing concentrations of FK506 re-
sulted in a concentration-dependent inhibition of OAG-evoked NCCE,
which might be indicative of a potential role of FKBPs in NCCE
(Fig. 1B). A signiﬁcant reduction of 47.0±8.0% (P b 0.01; n=6)was ob-
served using 10 μM of FK506, as previously shown in neurons [32,44],
but the higher effect was observed at the concentration of 50 μM
(69.0 ± 5.0% of control; P b 0.001; n = 6), therefore, we have used
this concentration throughout the study, as previously reported [45].
FK506 (50 μM) was still able to reduce OAG-evoked NCCE in platelets
previously incubated for 30 min with 100 nM of cypermethrin, a
speciﬁc calcineurin (CaN) antagonist (Fig. 1C); thus suggesting that
although part of the effect observed using FK506might relay on its indi-
rect regulatory role over CaN, a bigger inhibition is found in the pres-
ence of FK506; hence, we cannot consider that the FK506-dependent
NCCE impairment is based on the inhibition CaN activity exclusively,
as previously reported by others [46,47].
3.2. Immunophilins regulate NCCE through TRPC6
NCCE in human platelets has been reported to be mainly conducted
through TRPC6 and TRPC3 channels [11,13]. In order to investigate
whether TRPC6 is regulated by immunophilins, we perform a series ofFig. 4. FKBP25 interacts with TRPCs in human platelets. Human platelets were incubated
for 5 min in the absence or presence of FK506 (50 μM), and they were subsequently stim-
ulatedwith OAG for 1 min (100 μM) in HBS-rich Ca2+medium or kept under resting con-
ditions. Upon stimulation timewas over, plateletswereﬁxed bymixingwith RIPA. FKBP25
was immunoprecipitated from the cell fragments solution by incubating overnight with
1 μg/mL of anti-FKBP25 and agarose bead conjugated with protein A. Upon washing,
immunoprecipitated complexes were analyzed by performing Western blotting using
anti-TRPC3, anti-TRPC6 and anti-TRPC1 antibodies. Reprobing of the membranes was
done with either anti-FKBP25 to corroborate the homogeneity of the samples loaded in
the gel (data not shown). Images in the panels are representative of four independent ex-
periments, while histograms represent the changes in the protein complexes expressed as
the percentage and the S.E.M respect to control resting platelets. *, **, ***: represent
P b 0.05, b0.01, and b0.001 with respezct to control resting platelets; $$$: P b 0.001 with
respect to OAG stimulated platelets but non-treated with FK506.
Fig. 5. FKBP25 and FKBP38 interact with TRPC6 but not with other TRPCs in murine
platelets. Platelets drawn fromWT (A) or TRPC6−/− (B) mice were suspended in tyrode's
Ca2+-richmedium (300 μMwas added), and thenwere incubated for 5min in the absence
or presence of FK506 (50 μM), after which they were stimulated for 1 min with OAG
(100 μM)or kept under resting conditions, and ﬁnally ﬁxed using RIPA. Immunoprecipita-
tion of the proteins of interest was achieved by incubating the cell sample solutions with
either anti-TRPC6 (A) or anti-FKBP25 (B) or FKBP38 (B) and beads of agarose conjugated
with protein A. Immunoprecipitated protein complexes were analyzed by Western blot-
ting using anti-FKBP25 (A) and anti-FKBP38 (A), or using anti-TRPC1 (B), anti-TRPC3
(B) and anti-TRPC6 (B). Reprobing of the membranes with the appropriate antibody con-
ﬁrmed that same amount of proteinswere loaded in each gel lane.WCL: whole cell lysate.
Images are representative of four independent experiments.
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mice [33,34]. As depicted in Fig. 2, TRPC6−/− exhibited a signiﬁcantly
reduced OAG response, which strongly indicates that TRPC6 plays a
relevant role in NCCE in these cells, as previously reported [48]. In
WT mice, FK506 reduced OAG-induced NCCE by 33.6 ± 4.9%
(Fig. 2A; P b 0.001; n = 9), while it was without effect in platelets
from TRPC6−/− mice (Fig. 2B), thus suggesting that the effect of
FK506 was mediated through TRPC6. These ﬁndings were further sup-
ported by patch-clamp analysis in HEK293 cells constitutively overex-
pressing TRPC6. As shown in Fig. 3A, inward and outward TRPC6
current resulted modiﬁed by preincubating cells with FK506 for
5 min. Ga3+ was added to the cells at the end of the experiment to
conﬁrm OAG-induced TRPC6 activation. Our results indicate a reduc-
tion of 75.2 ± 4.4% (P b 0.001; n = 8, Fig. 3A) in the current density
through TRPC6 channel in the presence of FK506 as compared with
control untreated cells. Similarly, we have found that NCCE induced
by stimulating TRPC6-overexpressing HEK293 with 100 μM OAG was
reduced in the presence of FK506 by 59.5 ± 22.4% (Fig. 3B; P b
0.001; n = 4).
3.3. FKBP25 interacts with TRPCs
FKBPs interact with TRPCs in a number of cell types. In non-
excitable cells, we and others have recently identiﬁed FKBP52 and
FKBP12 as possible regulators of the SOC channels Orai1 and
TRPC1 [29,31,32,49]. Here, we have looked for alternative
immunophilins such as FKBP25 and FKBP38 that are receiving
more attention from the scientiﬁc community due to their role in
cell survival and subsequently cancer progression. As shown in
Fig. 4, in human platelets, FKBP25 was found to associate with
TRPC6 and TRPC3 under resting conditions. FKBP25 and TRPC6 cou-
pling was enhanced by 24.7 ± 10.9% (P b 0.01; n = 4; Fig. 4A) upon
platelet stimulation with OAG (100 μM) for 1 min, which was unaf-
fected by treatment with FK506 (50 μM) for 5 min. Stimulation
with OAG had no effect on the association between FKBP25 and
TRPC3, which was detectable under resting conditions (P N 0.05;
n = 4). Interestingly, FKBP25 was also found to interact with
TRPC1 under resting conditions and a signiﬁcant increase of
39.1 ± 15.3% (P b 0.001; n = 4; Fig. 4C) was induced by OAG. Treat-
ment for 5 min with FK506 signiﬁcantly reduced by 79.5 ± 13.2%
OAG-evoked coupling between FKBP25 and TRPC1 (Fig. 4C; P b
0.001; n = 4). Concerning FKBP38, we did not found detectable in-
teraction between this immunophilin and TRPC channels (data not
shown).
By evaluating these patterns of interaction between the
immunophilins and the different TRPCs, it seems that TRPC6 plays a
more relevant role than TRPC3 during the coupling process evoked by
OAG. Hence, we reproduced the same experimental protocols in plate-
lets from TRPC6−/− mice. As shown in Fig. 5, in platelets from WT
mice, FKBP25 and FKBP38 were found to associate with TRPC6
(Fig. 5A; n = 3) and this interaction was impaired in the murine
TPRC6−/− mice (Fig. 5B), which suggests that FKBP25 and FKBP38
might regulate NCCE by interaction with TRPC6, at least in mice plate-
lets. Interestingly, we have not observed compensation of TRPC6 with
TRPC3 in TPRC6−/− mice (see Fig. 5B middle panel where TRPC3 ex-
pression in WT and TRPC6−/− is analyzed by Western blotting) (WCL:
whole cell lysate).
Functional TRPCs are supposed to be located in the plasma mem-
brane of platelets; however current evidence indicates that TRPC1, 3
and 6 might be also found in intracellular locations, such as the expres-
sion of TRPC6 in the dense tubular system of murine platelets and
TRPC3 in the mitochondrial membrane in brain and liver cells [50,
51]. Thus, we explored whether the coupling between FKBPs and
TRPC6 takes place in the plasma membrane by biotinylation. As
shown in Fig. 6A, FKBP25 and FKBP38 was found in the biotinylated
samples, and while FKBP25 location was not altered upon plateletstimulation with OAG (100 μM), FKBP38 presence in the membrane
was signiﬁcantly reduced upon platelet stimulation (Fig. 6A, middle
panel).
Fig. 6. FKBP25 and FKBP38 are located at the plasmamembrane andwould interactwith other FKBPs and CaM.Human platelets suspended inHBS-rich Ca2+medium(300 μMofCaCl2was
added) were preincubated in the absence (A–E) or presence of FK506 (50 μM for 5 min, D–E) and were subsequently stimulated with OAG for 1 min (100 μM) or kept under resting
conditions. Uponwhich platelets were subjected to biotinylation (A) or immunoprecipitation protocols (B–E),which are performed as described inMaterials section. Anti-PMCA antibody
was used to verify that similar amounts of membrane protein were loaded in the gel, while reproving with anti-FKBP38 was done as loading control (data not shown). Images are
representative of three independent experiments.
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We have further evaluated the association between TRPC6 and
TRPC3 in both murine and human platelets during NCCE activation. As
shown in Fig. 7A, during OAG-evoked NCCE (100 μM) a signiﬁcant in-
crease in the association between TRPC3 and TRPC6 was observed
(109.9 ± 3.0%; P b 0.05; n = 4). This interaction was signiﬁcantly re-
duced by incubating platelets for 5 min with 50 μM FK506 (85.5 ±
4.8%; P b 0.05; n = 4). OAG-evoked association between TRPC6 and
TRPC3 resulted also impaired in platelets from WT mice incubated
with 50 μM FK506 (Fig. 7B; n = 4), which further support a role of
FKBPs in the assembly of the TRPC6/TRPC3 heteromultimeric complex.
Orai1 has been reported as the main SOC channel, with a role for
TRPC channels in receptor-operated Ca2+ inﬂux. In order to ascertain
whether TRPC6 plays a role in human platelet physiology, we per-
formed experiments where platelet aliquots of 400 μL were incubatedwith either 1 μg/mL anti-TRPC6 antibody, or anti-TRPC6 previously pre-
incubated with CAP, or rabbit IgG of the same nature as the anti-TRPC6
antibody. As observed in the Fig. Supplementary 1, a signiﬁcant reduc-
tion in the aggregation evoked by ADP (10 μM) was found in platelets
preincubated with anti-TRPC6 antibody, while incubation with anti-
TRPC6 + CAP as well as with rabbit IgG was without effect. In the ab-
sence of speciﬁc TRPC6 inhibitors and taking into account that RNA-
based techniques are scarce in human platelets, this approach provides
evidence for a role of TRPC6 in human platelet physiology, in agreement
with a recent manuscript supporting a role for TRPC6 in platelet activa-
tion [52].
3.5. FKBP25 and FKBP38 silencing inhibits the activation of NCCE
As shown in Fig. 8, we have further explored the relevance of FKBP25
in NCCE in two different culture cell types, MEG-01 and HEK293 cells.
Fig. 7. Immunophilins participate in the formation of the NCCE heteromultimeric com-
plexes. Human (A) orWT mice (B) platelets were suspended in a HBS-Ca2+ rich medium
or tyrode's Ca2+-rich medium, respectively, and then were incubated for 5 min in the
presence or absence of FK506 (50 μM) and were subsequently stimulated with OAG
(100 μM) for 1min or left non-stimulated. Upon cellﬁxation bymixingwith equal volume
of RIPA, protein of interest were immunoprecipitated using anti-TRPC6 and beads of aga-
rose conjugated with protein A. Immunoprecipitated proteins were solved by Western
blotting using anti-TRPC3 antibody. Images in the panel are representative of four inde-
pendent experiments. As shown, reprobing of the membranes was done with anti-
TRPC6 antibody to corroborate the homogeneity of the sample loaded in each gel lane.
*: P b 0.05 respect control platelet under resting conditions, and $: P b 0.05 respect to con-
trol platelets stimulated with OAG.
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the OAG-evoked NCCE by 52.1 ± 14.4% (P b 0.001; n = 4) in
MEG-01 cells (Fig. 8A), and by 38.9 ± 11.9% (P b 0.001; n = 4) in
HEK293 (Fig. 8B), respectively. Cell transfection with the emptyplasmid did not alter NCCE evoked by OAG (100 μM) in HEK293
cells; hence demonstrating that neither transfection nor introduc-
tion of a exogenous genetic material affect to this mechanism, and
supporting the fact that the NCCE inhibition registered in cells
transfected with siRNA was likely due to the reduction in the
amount of the targeted protein.
Similarly, treatment of MEG-01 and HEK293 cells with siRNA
FKBP38 signiﬁcantly attenuated OAG-evoked NCCE by 37.59 ± 15.5%
(P b 0.001; n= 4) and 48.5 ± 14.4% (P b 0.001; n= 4). Overexpression
of GFP-FKBP38 in HEK293 did not alter OAG-evoked Ca2+ entry com-
pared to WT cells (cells transfected but non-expressing the FKBP38
fused protein) (see Fig. 8B left hand side graph at the bottom of the
ﬁgure).
Genetic manipulation of FKBP25 and FKBP38 in MEG-01 and
HEK293 cells did not alter the expression of TRPC3 or TRPC6
(data not show), but slightly, although non-signiﬁcantly, attenuat-
ed the TRPC6/TRPC3 coupling, while transfecting with siRNA con-
trol was without effect in the TRPC6/TRPC3 coupling (data not
shown).4. Discussion
Human platelets have different mechanisms for Ca2+ entry. SOCE, a
mechanism regulated by the ﬁlling state of the Ca2+ stores, has been
shown to be conducted through Orai1 channels [53], although other
channels like TRPC1or TRPC6 are also involved inCa2+ entry, as demon-
strated in different cell types, including the megakaryoblastic cell line,
MEG01 [45,54,55]. Additionally, TRPC6 also acts as a non-
capacitative channel in platelets [48,51], and, as for other TRPC chan-
nels, it might be subjected to different postraductional modiﬁcations
that affect their permeability [4,35,56–58]. TRPC6 is one of the two
classic TRPCs involved in NCCE operated by DAG. The relevance of
NCCE in human platelets is evidenced in patients suffering type 2 di-
abetes mellitus, where an enhanced NCCE through TRPC6 seems to
underlie the hyperaggregability state observed in these patients
[59–61]. Here, we have explored the possible role of immunophilins
in the regulation of NCCE stimulated by OAG, a cell-permeable DAG
synthetic derivative.
Our results provide clear evidence for a role of immunophilins in
NCCE that can be attributed to the activity of the FKBP members, and
not just due to the indirect inhibitory effect of FK506 on CaN, as previ-
ously suggested by others [44,62]. Inhibition of immunophilins did not
alter NCCE in platelets from mice lacking TRPC6, which provides a
strong evidence in favor of that TRPC6 might be the target channel of
the immunophilin activity [63].
Previous studies have reported direct interaction of immunophilins
with TRPC channels. For instance, in neurons, FKBP52 presents two pos-
sible binding regions in both extremes of the TRPC1 structure
(19LPSSP23 and 644LPPPF648), being the latest region overlapped with
the homer binding region, and it is close to the STIM1 interaction region
(two aspartate residues immediately after TRP box 2) [32]. Interaction
between immunophilins and TRPC6 might occur through a unique res-
idue, such as occurswith FKBP12 that recognizes the Ser768 and Ser714
of TRPC6 upon their phosphorylation by PKC [63].
We describe here that the interaction between TRPC6 and
FKBP25 occurs under resting conditions and is modulated upon
stimulation with OAG. FKBP25 has been described to act as a nucle-
ar factor that has the ability of interacting with pre-rRNA, thus af-
fecting to ribosomal protein synthesis [64], and subsequently, to
the general protein expression in the cells. FKBP25 was shown to
be downregulated by rapamycin and FK506, having more afﬁnity
for rapamycin than FK506, hence it represents a good candidate
for the alterations observed in patients suffering cancer or neurode-
generative disorders, and are medicated with these macrolides
[65–67].
Fig. 8. Silencing of FKBP25 and FKBP38 reduces NCCE inMEG-01 and HEK293 cells. MEG-01 (A) and HEK293 (B) cells were transfected with 2 μg/mL of siRNA against FKBP25 and FKBP38
orwere left non-transfected (WT). Internal experimental controls consisted in transfectingMEG-01 cellswith 2 μg/mL of siRNA control. Additionally, HEK293was transfectedwith 2 μg/mL
of either an empty overexpressing plasmid (GFP-plasmid) orwith theplasmid containing theGFP-FKBP38 fusedprotein. The reduction in the expression of the FKBPswas conﬁrmedeither
byWestern blotting (right hand side images) or by epiﬂuorescentmicroscopy (in case of theHEK293 transfectedwith theGFP-FKBP38 protein; Scale bar is 15 μm), which occurred 72 h or
24 h after transfection, respectively. After conﬁrming that cells were geneticallymodiﬁed they were loaded with fura-2 andmounted in a perfusion chamber of a single cells imaging sys-
tem. Cells were then perfused with HBS-rich Ca2+ (50 μM) containing, and were then stimulated with OAG solution (containing 300 μM of CaCl2). Additionally, OAG-evoked coupling
between TRPC6 and TRPC3 was explored in both cell types and compared to control non-transfected cells (WT) (Right hand side images). Reprobing of the membranes with anti-
TRPC6 antibodies or anti-actin antibodies was done following the appropriate protocols in order to corroborate that similar amount of proteins was loaded in each gel lane. Graphs rep-
resent themean± standard deviation of 3–4 independent cell transfections;meanwhile, histograms represent themean of the percentage respect to control± S.E.M. Images in the panels
are representative of 3 to 4 independent experiments. ***: P b 0.001.
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positive regulator of OAG-dependent calcium entry, as well as con-
trary to previous publication that limit its intracellular distribution
to the ER and nucleus, we have detected FKBP25 at the plasma
membrane of platelets by performing biotinylation experiments,
but the amount seems to be scarce compared with the cytosolic lo-
cation. Furthermore, we found that it associates with other FKBPs
like FKBP38, so perhaps favoring a FK506-dependent inhibition of
FKBP38 non-described yet. The interaction of FKBP25 with TRPC6
and the effect of FKBP25 downregulation on NCCE in MEG01 and
HEK293, indicate that FKBP25 might be a positive regulator of
TRPC6. Although non-signiﬁcant, a reduction in TRPC6/TRPC3 inter-
action could be observed in these cells transfected with the siRNA
FKBP25.
FKBP38 is an immunophilin activated by CaM/Ca2+ after intra-
cellular Ca2+ bursts [68]. FKBP38 N-terminal domain presents a
charge-sensitive functional loop with afﬁnity for Ca2+ that regu-
lates the interaction with their substrates [70]. We have not detect-
ed direct interaction of FKBP38 with TRPC6; however, RNAi-based
analysis revealed downregulation of OAG-evoked NCCE in both,
MEG-01 and HEK293 cells. Moreover, the biotinylation experi-
ments together with the epiﬂuorescence microscopy observations
done in HEK293 overexpressing GFP-FKBP38, which evidenced a
random cytosolic distribution of this protein, lead us to conclude
that FKBP38 might be found in intracellular locations different
from the ER and mitochondrial associated membranes described
by others [73]. In contrast, the overexpression of FKBP38 did not
enhance NCCE activated by OAG which was unexpected and
might indicate that it could be required somehow during the acti-
vation of this mechanism, so this part will deserve future research
to ﬁnd out the precise modulating role of FKBP38 over TRPC6 dur-
ing NCCE.
Regarding the role of FKBP38, we would suggest that it would
have a regulatory role on TRPC6. Nevertheless, according to the IP
control experiments performed (data not shown), FKBP38/TRPC6
interaction would not occur directly, but it would happen through
other intermitted proteins like FKBPs (perhaps FKBP25) or CaM in-
stead, which were found here to associate with this channels as
well as it has been previously reported by other research groups
[74,75]. Nowadays, there are contradictory results in the literature
regarding the effect of FK506 in FKBP38 PPIase activity, like FK506
binding domain is not altered in presence of FK506, like it does in
the FKBP12 structure [76]. On the contrary, other research groups
have reported inhibition of FKBP38 activity in the presence of
FK506; this inhibition might result of its interaction either with
other immunophilins or with CaM, all of them are shown in the
present study [69,71,72]. In fact, incubation of platelets with
FK506 and subsequent stimulation with OAG evoked enhanced
CaM/FKBP38 interaction. Other nonimmunosuppresive and neuro-
trophic compound, GPI1046, was also able to inhibit FKBP38
when combined in a functional complex with CaM/Ca2+ [22].
Hence, FKBP25 and other immunophilins might be favoring the
generation of the full active NCCE channels resulting of the complex
between both channels with the immunophilins, and FKBP38 might
modulate this macrocomplex during NCCE in non-excitable cells, al-
though the mechanisms underlying this regulation deserve further
studies.
Summarizing, here we describe for the ﬁrst time the interaction
between FKBP25 and TRPC6, which plays a relevant role in the acti-
vation of NCCE. FKBP25 might interact with the NCCE channels
through TRPC6, as demonstrated by using platelets from TRPC6-
deﬁcient mice. FKBP38 also play a role in NCCE although the mecha-
nism underlying this process seems different from that reported to
FKBP25.
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